Robert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, Serigne N Lo, Robyn P M Saw, Alexander H R Varey, Richard A Scolyer, Georgina V Long, John F Thompson, Piotr Rutkowski, Ulrich Keilholz, Alexander C J van Akkooi, Cornelis Verhoef, David van Klaveren, Dirk J Grünhagen
BACKGROUND: The introduction of adjuvant systemic treatment for patients with high-risk melanomas necessitates accurate staging of disease. However, inconsistencies in outcomes exist between disease stages as defined by the American Joint Committee on Cancer (8th edition). We aimed to develop a tool to predict patient-specific outcomes in people with melanoma rather than grouping patients according to disease stage. METHODS: Patients older than 13 years with confirmed primary melanoma who underwent sentinel lymph node biopsy (SLNB) between Oct 29, 1997, and Nov 11, 2013, at four European melanoma centres (based in Berlin, Germany; Amsterdam and Rotterdam, the Netherlands; and Warsaw, Poland) were included in the development cohort...
April 2024: Lancet Oncology